Drug interaction concerns may affect HIV treatment adherence among transgender women

(NIH/National Institute of Allergy and Infectious Diseases) Transgender women -- at high risk of HIV acquisition -- are a key population for HIV prevention and treatment efforts. A study supported by NIH and Gilead Sciences reveals that more than half of transgender living with HIV in Los Angeles were concerned that taking both antiretroviral therapy to treat HIV and feminizing hormone therapy (HT) may cause harmful drug-drug interactions. Many surveyed cited these concerns as a reason for not t...